Suppr超能文献

一种丙型肝炎病毒反应性T细胞受体的鉴定,该受体识别靶细胞时不需要CD8。

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition.

作者信息

Callender Glenda G, Rosen Hugo R, Roszkowski Jeffrey J, Lyons Gretchen E, Li Mingli, Moore Tamson, Brasic Natasha, McKee Mark D, Nishimura Michael I

机构信息

Department of Surgery, University of Chicago Hospitals, Chicago, IL, USA.

出版信息

Hepatology. 2006 May;43(5):973-81. doi: 10.1002/hep.21157.

Abstract

Hepatitis C virus (HCV) has been reported to elicit B and T cell immunity in infected patients. Despite the presence of antiviral immunity, many patients develop chronic infections leading to cirrhosis, hepatocellular carcinoma, and liver failure that can require transplantation. We have previously described the presence of HLA-A2-restricted, HCV NS3-reactive cytotoxic T lymphocytes (CTL) in the blood of HLA-A2- liver transplantation patients that received an HLA-A2+ liver allograft. These T cells are analogous to the "allospecific" T cells that have been described in hematopoietic stem cell transplantation patients. It has been speculated that allospecific T cells express high-affinity T cell receptors (TCRs). To determine if our HCV-reactive T cells expressed TCRs with relatively high affinity for antigen, we identified and cloned a TCR from an allospecific HLA-A2-restricted, HCV:NS3:1406-1415-reactive CD8+ T cell clone and expressed this HCV TCR in Jurkat cells. Tetramer binding to HCV TCR-transduced Jurkat cells required CD8 expression, whereas antigen recognition did not. In conclusion, based on the reactivity of the TCR-transduced Jurkat cells, we have identified a TCR that transfers anti-HCV reactivity to alternate effectors. These data suggest this high affinity HCV-specific TCR might have potential new immunotherapic implications.

摘要

据报道,丙型肝炎病毒(HCV)可在感染患者中引发B细胞和T细胞免疫。尽管存在抗病毒免疫,但许多患者仍会发展为慢性感染,导致肝硬化、肝细胞癌和肝衰竭,可能需要进行肝移植。我们之前曾描述过,在接受HLA - A2 +肝移植的HLA - A2 -肝移植患者血液中存在HLA - A2限制性、HCV NS3反应性细胞毒性T淋巴细胞(CTL)。这些T细胞类似于造血干细胞移植患者中所描述的“同种特异性”T细胞。据推测,同种特异性T细胞表达高亲和力的T细胞受体(TCR)。为了确定我们的HCV反应性T细胞是否表达对抗原具有相对高亲和力的TCR,我们从一个同种特异性HLA - A2限制性、HCV:NS3:1406 - 1415反应性CD8 + T细胞克隆中鉴定并克隆了一个TCR,并在Jurkat细胞中表达了这种HCV TCR。四聚体与HCV TCR转导的Jurkat细胞结合需要CD-8表达,而抗原识别则不需要。总之,基于TCR转导的Jurkat细胞的反应性,我们鉴定出了一种可将抗HCV反应性转移至其他效应细胞的TCR。这些数据表明,这种高亲和力的HCV特异性TCR可能具有潜在的新免疫治疗意义。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验